Edition:
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

30.27USD
24 May 2017
Change (% chg)

-- (--)
Prev Close
$30.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
326,211
52-wk High
$44.38
52-wk Low
$24.47

Select another date:

Thu, May 4 2017

BRIEF-Emergent Biosolutions reports Q1 revenue $116.9 million

* Emergent Biosolutions reports first quarter 2017 financial results; reaffirms 2017 guidance

BRIEF-Emergent Biosolutions signs $53 mln modification to Barda contract for manufacture of botulism antitoxin

* Emergent Biosolutions signs $53 million modification to Barda contract for the manufacture of botulism antitoxin

BRIEF-Emergent Biosolutions awarded $100 mln BARDA contract

* Emergent Biosolutions awarded $100 million BARDA contract for Biothrax deliveries to the strategic national stockpile

BRIEF-Emergent Biosolutions reports Q4 EPS $0.67

* Fy2017 earnings per share view $2.08, revenue view $543.1 million -- Thomson Reuters I/B/E/S

BRIEF-Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax

* Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax

BRIEF-Aptevo Therapeutics receives $20 mln payment from Emergent Biosolutions

* Aptevo Therapeutics receives $20 million payment from Emergent Biosolutions

BRIEF-Emergent Biosolutions announces preliminary 2016 financial results

* Emergent Biosolutions announces preliminary 2016 financial results and provides 2017 financial outlook

Select another date:

More From Around the Web